Mitochondrial Peptide SS-31: What It Is, How It Works, and What Research Shows

SS-31, also known as elamipretide, MTP-131, or Bendavia, is a synthetic tetrapeptide that concentrates inside mitochondria and binds to cardiolipin on the inner membrane. Researchers study the mitochondrial peptide SS-31 for its ability to stabilize cristae, lower reactive oxygen species, and support ATP production. It is currently a research chemical in the United States and is not FDA-approved for human use.

How SS-31 Works in the Mitochondria

SS-31 is a four-amino-acid sequence — D-Arg-Dmt-Lys-Phe-NH2 — built with alternating aromatic and positively charged residues. That structure lets it cross cell membranes and accumulate in the inner mitochondrial membrane, where cardiolipin sits. Elamipretide is the formal drug name for SS-31, and the same molecule has also appeared in the literature as MTP-131 and Bendavia.

Cardiolipin is a phospholipid that helps fold the inner membrane into cristae and anchors several proteins in the electron transport chain. When cardiolipin is oxidized or displaced, cristae lose their shape, electron transport becomes less efficient, and the cell releases more reactive oxygen species.

In laboratory and animal models, SS-31 binds cardiolipin and appears to:

• Preserve cristae structure and membrane curvature
• Reduce mitochondrial reactive oxygen species
• Improve electron transport chain efficiency and ATP output
• Limit release of pro-apoptotic factors after cellular stress

These findings come mainly from cell cultures and animal models. Human trial results have been mixed, which is important context for anyone reading confident marketing claims.

What Clinical Research Shows So Far

Elamipretide has moved through several human trials across different conditions. Results have been inconsistent, and most late-stage programs have missed their primary endpoints.

The pattern is consistent: measurable mitochondrial effects in the lab have not reliably translated into patient-level benefit in large human trials. That does not mean the mechanism is wrong — it means the clinical evidence is still weak.

SS-31 Compared With Other Mitochondrial Peptides

Interest in the mitochondrial peptide ss 31 tends to rise alongside broader interest in mitochondrial health, and it is often discussed next to mitochondria-derived peptides and metabolic compounds. The table below outlines the main differences.

Because the mechanisms differ, some researchers look into ss-31 and mots-c together when designing mitochondrial studies — one targeting membrane integrity, the other targeting metabolic signaling. Any such combination remains speculative outside a controlled research setting.

Regulatory Status and Legal Considerations

Elamipretide has not received FDA approval for any indication. Stealth BioTherapeutics has pursued approval for Barth syndrome, but regulators declined to approve the drug after an advisory committee questioned whether the benefits outweighed the risks.

Because of that, SS-31 sold in the US is labeled for research use only. It is not a dietary supplement and it is not a legal prescription medication. Purchasing it for personal injection falls outside the intended use of these products.

Dosing, Handling, and Research Protocols

There is no FDA-approved human dose of SS-31. Research protocols vary widely, and animal doses do not translate directly to people. Anyone reviewing ss-31 peptide dosing should treat published protocols as laboratory-specific rather than as medical guidance.

Practical handling notes for laboratory work:

1. Store lyophilized vials at -20 °C or lower, protected from light.
2. Reconstitute with bacteriostatic water or the solvent specified by the supplier.
3. Aliquot after reconstitution to avoid repeated freeze-thaw cycles.
4. Use sterile technique and record lot numbers for reproducibility.

The most common vial sizes are 10 mg and 30 mg. A larger vial is often chosen for multi-week studies because it reduces the number of separate purchases, and ss-31 30mg listings typically include a certificate of analysis from the manufacturer.

Safety and Side Effects of SS-31

In human trials, the most frequently reported ss 31 side effects were mild injection site reactions such as redness, pain, or swelling. Other reported events included headache and nausea, and these were generally transient.

Those data come from short, supervised studies. Long-term safety, interactions with prescription medications, and effects during pregnancy or in people with kidney or liver disease have not been well studied. Anyone considering use should talk with a healthcare professional rather than rely on forum reports.

SS-31 is an investigational compound. No regulator has approved it for human use, and self-dosing carries unknown risks.

Sourcing, Purity, and Third-Party Testing

Quality varies widely between suppliers, so documentation matters more than price. Before you decide where to buy ss-31 peptide, look for an independent certificate of analysis that shows HPLC purity and mass spectrometry confirmation.

For research buyers in the US, the reliable signals are:

• A batch-specific COA, not a generic sample document
• HPLC purity above 98% with a visible chromatogram
• Mass spectrometry data matching the expected molecular weight
• Clear labeling that the product is for research use only

Domestic suppliers usually list turnaround times and cold-chain packaging options. If a listing makes medical claims or promises clinical results, that is a red flag rather than a selling point.

Bottom Line

SS-31 is a well-characterized mitochondrial-targeting tetrapeptide with a plausible mechanism and a mixed clinical record. Laboratory evidence for cardiolipin binding and cristae protection is fairly solid; evidence that it improves human disease outcomes is not. It remains unapproved, and personal use is experimental.